** Shares of drug developer Plus Therapeutics PSTV.O more than double to 38 cents
** Co says the U.S. FDA has cleared its application to begin human trials for its experimental brain cancer therapy
** The trial is funded by a $3 million research grant from the U.S. Department of Defense, co says
** The early-stage trial is aimed to determine the maximum tolerated dose safety and tolerability of the therapy called Reyobiq in pediatric patients aged six to 21 years
** The company is testing the therapy to treat aggressive brain tumors called high-grade glioma and ependymoma
** Including session moves, stock down 68.1% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。